664 related articles for article (PubMed ID: 33595663)
1. Evaluation of Optimal Diastolic Blood Pressure Range Among Adults With Treated Systolic Blood Pressure Less Than 130 mm Hg.
Li J; Somers VK; Gao X; Chen Z; Ju J; Lin Q; Mohamed EA; Karim S; Xu H; Zhang L
JAMA Netw Open; 2021 Feb; 4(2):e2037554. PubMed ID: 33595663
[TBL] [Abstract][Full Text] [Related]
2. Association Between Baseline Diastolic Blood Pressure and the Efficacy of Intensive vs Standard Blood Pressure-Lowering Therapy.
Foy AJ; Filippone EJ; Schaefer E; Nudy M; Ruzieh M; Dyer AM; Chinchilli VM; Naccarelli GV
JAMA Netw Open; 2021 Oct; 4(10):e2128980. PubMed ID: 34668944
[TBL] [Abstract][Full Text] [Related]
3. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.
Williamson JD; Supiano MA; Applegate WB; Berlowitz DR; Campbell RC; Chertow GM; Fine LJ; Haley WE; Hawfield AT; Ix JH; Kitzman DW; Kostis JB; Krousel-Wood MA; Launer LJ; Oparil S; Rodriguez CJ; Roumie CL; Shorr RI; Sink KM; Wadley VG; Whelton PK; Whittle J; Woolard NF; Wright JT; Pajewski NM;
JAMA; 2016 Jun; 315(24):2673-82. PubMed ID: 27195814
[TBL] [Abstract][Full Text] [Related]
4. [The SPRINT Research. A Randomized Trial of Intensive versus Standard Blood-Pressure Control].
Widimský J
Vnitr Lek; 2016 Jan; 62(1):44-7. PubMed ID: 26967236
[TBL] [Abstract][Full Text] [Related]
5. Effects of intensive blood-pressure control in type 2 diabetes mellitus.
; Cushman WC; Evans GW; Byington RP; Goff DC; Grimm RH; Cutler JA; Simons-Morton DG; Basile JN; Corson MA; Probstfield JL; Katz L; Peterson KA; Friedewald WT; Buse JB; Bigger JT; Gerstein HC; Ismail-Beigi F
N Engl J Med; 2010 Apr; 362(17):1575-85. PubMed ID: 20228401
[TBL] [Abstract][Full Text] [Related]
6. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease.
Cooper-DeHoff RM; Gong Y; Handberg EM; Bavry AA; Denardo SJ; Bakris GL; Pepine CJ
JAMA; 2010 Jul; 304(1):61-8. PubMed ID: 20606150
[TBL] [Abstract][Full Text] [Related]
7. Diastolic Hypotension May Attenuate Benefits from Intensive Systolic Targets: Secondary Analysis of a Randomized Controlled Trial.
Lee TC; Cavalcanti RB; McDonald EG; Pilote L; Brophy JM
Am J Med; 2018 Oct; 131(10):1228-1233.e1. PubMed ID: 29906425
[TBL] [Abstract][Full Text] [Related]
8. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension.
Weber MA; Bakris GL; Hester A; Weir MR; Hua TA; Zappe D; Dahlof B; Velazquez EJ; Pitt B; Jamerson K
Am J Med; 2013 Jun; 126(6):501-8. PubMed ID: 23541376
[TBL] [Abstract][Full Text] [Related]
9. 2014 Eighth Joint National Committee panel recommendation for blood pressure targets revisited: results from the INVEST study.
Bangalore S; Gong Y; Cooper-DeHoff RM; Pepine CJ; Messerli FH
J Am Coll Cardiol; 2014 Aug; 64(8):784-93. PubMed ID: 25145522
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
[TBL] [Abstract][Full Text] [Related]
11. Effect of Lowering Diastolic Pressure in Patients With and Without Cardiovascular Disease: Analysis of the SPRINT (Systolic Blood Pressure Intervention Trial).
Khan NA; Rabkin SW; Zhao Y; McAlister FA; Park JE; Guan M; Chan S; Humphries KH
Hypertension; 2018 May; 71(5):840-847. PubMed ID: 29581214
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.
Vidal-Petiot E; Ford I; Greenlaw N; Ferrari R; Fox KM; Tardif JC; Tendera M; Tavazzi L; Bhatt DL; Steg PG;
Lancet; 2016 Oct; 388(10056):2142-2152. PubMed ID: 27590221
[TBL] [Abstract][Full Text] [Related]
13. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Weber MA; Williams B; Yusuf S
Lancet; 2017 Jun; 389(10085):2226-2237. PubMed ID: 28390695
[TBL] [Abstract][Full Text] [Related]
14. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
[TBL] [Abstract][Full Text] [Related]
15. Systolic blood pressure levels among adults with hypertension and incident cardiovascular events: the atherosclerosis risk in communities study.
Rodriguez CJ; Swett K; Agarwal SK; Folsom AR; Fox ER; Loehr LR; Ni H; Rosamond WD; Chang PP
JAMA Intern Med; 2014 Aug; 174(8):1252-61. PubMed ID: 24935209
[TBL] [Abstract][Full Text] [Related]
16. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
JAMA; 2002 Sep; 288(12):1491-8. PubMed ID: 12243636
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
Blood Pressure Lowering Treatment Trialists' Collaboration
Lancet; 2021 May; 397(10285):1625-1636. PubMed ID: 33933205
[TBL] [Abstract][Full Text] [Related]
18. Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance.
Fleg JL; Evans GW; Margolis KL; Barzilay J; Basile JN; Bigger JT; Cutler JA; Grimm R; Pedley C; Peterson K; Pop-Busui R; Sperl-Hillen J; Cushman WC
Hypertension; 2016 Oct; 68(4):888-95. PubMed ID: 27504006
[TBL] [Abstract][Full Text] [Related]
19. Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
Böhm M; Schumacher H; Teo KK; Lonn E; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder R; Weber M; Sliwa K; Williams B; Yusuf S
Eur Heart J; 2018 Sep; 39(33):3105-3114. PubMed ID: 29873709
[TBL] [Abstract][Full Text] [Related]
20. Systolic and diastolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension and pre-frailty or frailty status.
Zhu J; Yang K; Liu W
J Clin Hypertens (Greenwich); 2024 May; 26(5):514-524. PubMed ID: 38552135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
